Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $11.60.

ZURA has been the subject of a number of research analyst reports. Leerink Partners raised Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Wedbush initiated coverage on Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th.

Insiders Place Their Bets

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of Zura Bio stock in a transaction that occurred on Thursday, February 26th. The stock was bought at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the transaction, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. This represents a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 14.23% of the company’s stock.

Institutional Trading of Zura Bio

Several hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in shares of Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares during the period. Siren L.L.C. bought a new stake in shares of Zura Bio in the 4th quarter worth approximately $6,812,000. Boothbay Fund Management LLC purchased a new position in Zura Bio in the third quarter valued at approximately $3,568,000. VR Adviser LLC lifted its stake in Zura Bio by 15.4% in the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock valued at $28,008,000 after purchasing an additional 713,899 shares during the last quarter. Finally, Braidwell LP grew its holdings in Zura Bio by 28.6% during the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock valued at $16,665,000 after purchasing an additional 707,583 shares during the period. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

Shares of ZURA stock opened at $6.12 on Friday. Zura Bio has a 52-week low of $0.97 and a 52-week high of $7.44. The company has a 50-day simple moving average of $6.16 and a two-hundred day simple moving average of $4.51. The company has a market capitalization of $397.92 million, a price-to-earnings ratio of -9.42 and a beta of 0.18.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Tuesday, March 24th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, sell-side analysts forecast that Zura Bio will post -0.65 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.